More about Torrent Pharmaceuticals Limited
Fundamentals for Torrent Pharmaceuticals Limited
Regulatory Filings for Torrent Pharmaceuticals Limited
From Cost Center to Strategic Core: The Top 10 Trends Transforming Finance in 2026
CFOs Seize the Tech Purse Strings: How 2026 Budgets Are Fueling the AI Transformation
From Agentic AI to Tokenized Assets: The Fintech Trends Reshaping Financial Services
Forex Focus: How a Weakening Indian Rupee Could Reshape Markets in Q1 2026
Fundamentals for Torrent Pharmaceuticals Limited
Business Operations:
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including cardiovascular, central nervous system, gastro-intestinal, and women healthcare; and dermatology, diabetology, pain management, gynecology, oncology, and anti-infective, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.
Revenue projections:
Torrent Pharmaceuticals Limited's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.
Financial Ratios:
| currentRatio | 1.396000 |
|---|---|
| forwardPE | 41.999935 |
| debtToEquity | 33.400000 |
| earningsGrowth | 0.305000 |
| revenueGrowth | 0.143000 |
| grossMargins | 0.756870 |
| operatingMargins | 0.266200 |
| trailingEps | 63.290000 |
| forwardEps | 0.000000 |
With a current ratio of 1.396, TORNTPHARM has the liquidity needed to easily service its short-term debt. The company's cash reserves and current assets are sufficient, indicating that TORNTPHARM is in a strong position to meet its immediate financial obligations without difficulty.
Positive earnings and revenue growth for TORNTPHARM point to expected business expansion. The company is projected to continue growing its operations, as increasing profits and sales highlight a strong trajectory for further growth in the future.
With positive gross and operating margins, Torrent Pharmaceuticals Limited demonstrates strong profitability. This reflects the company's ability to manage costs and maintain healthy profits, showcasing effective operational efficiency and financial stability.
Price projections:
The steady upward revision of TORNTPHARM's price projections indicates growing confidence in the company's performance. Analysts are becoming increasingly optimistic about TORNTPHARM's future prospects and potential for growth.
Recommendation changes over time:
Analysts' buy bias for Torrent Pharmaceuticals Limited signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to Torrent Pharmaceuticals Limited, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
Understanding Divergent House Price Movements Worldwide
The 2026 Tariff Tipping Point: When Trade Policy Reaches the Consumer
From Caracas to Commodities: The Market Impact of U.S.–China Friction